175 results on '"Diez-Campelo M"'
Search Results
2. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
3. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS
4. CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
6. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS
7. Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
8. Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
9. Síndromes mielodisplásicos
10. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS
11. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)
12. P075 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW CYTOKINES AND CHEMOKINES CONCENTRATIONS IN MYELODISPLASTIC NEOPLASMS
13. P074 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS
14. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION
15. P041 - Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution: CLINICAL AND MOLECULAR CHARACTERIZATION OF PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS
16. O10 - CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES
17. Results of allogeneic stem cell transplantation in the Spanish MDS registry: Prognostic factors for low risk patients
18. P728: GENE EXPRESSION PROFILE REVELS T-LYMPHOCYTES ACTIVATION THROUGH CELL CYCLE PROGRESSION AND MITOCHONDRIAL METABOLISM REGULATION IN MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) AFTER LENALIDOMIDE TREATMENT
19. P783: SYSTEMIC THERAPY UTILIZATION AND HEMATOLOGIC OUTCOMES IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FINDINGS FROM A REAL-WORLD MEDICAL RECORD REVIEW STUDY IN THE US, UK, AND EUROPE (EU)
20. PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
21. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
22. P36 - Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: MESENCHYMAL STROMAL CELLS MAY ENHANCE RESIDUAL HEALTHY HAEMATOPOIESIS IN LOW-RISK MDS PATIENTS
23. P30 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: RELATION BETWEEN INMUNE CELL POPULATIONS AND MALIGNANT CLONE MUTATIONAL STATUS IN MYELODYSPLASTIC SYNDROMES
24. P31 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: PHENOTYPE AND GENOTYPE OF NATURAL KILLERS IN MYELODISPLASITIC SYNDROME
25. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)
26. O20 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCORPORATION OF COHESIN MUTATIONAL DATA INTO CURRENT IPSS-R CLASSIFICATION REFINES THE PROGNOSTIC STRATIFICATION OF VERY LOW/LOW-RISK MYELODYSPLASTIC SYNDROMES
27. Toxic iron species in lower-risk myelodysplastic syndrome patients : course of disease and effects on outcome
28. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
29. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
30. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome
31. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy
32. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation
33. Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Acute Graft-versus-Host Disease (GVHD)
34. Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use
35. P39 The Humanistic Burden of Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes on Patients and Caregivers: Qualitative Research Findings
36. DETECTION OF CLONAL PLASMA CELL IN PERIPHERAL BLOOD BY NEXT GENERATION FLOW IN MULTIPLE MYELOMA PATIENTS DURING TREATMENT. RELATIONSHIP WITH BONE MARROW AND SERUM IMMUNOFIXATION
37. Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia
38. 41 - Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation
39. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group
40. MUTATIONAL SIGNATURE AND CLONAL ARCHITECTURE OF LOW RISK MYELODYSPLASTIC SYNDROMES
41. TRANSCRIPTOME ASSESSMENT OF DNA REPAIR GENES IN CHRONIC MYELOMONOCYTIC LEUKEMIA: SYNTHETIC LETHALITY TARGETS
42. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R)
43. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes
44. Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
45. P2442Assessment of iron overload and cardiac disease in patients with transfusion-dependent myelodysplastic syndromes with cardiac magnetic resonance new sequences
46. Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML
47. Calculating IPSS-R by Enumerating Bone Marrow Blasts from Nonerythroid Cellularity Improves Outcome Prediction in MDS with Erythroid Predominance
48. The Prognostic Evaluation of Myelodysplastic Syndromes with Ring Sideroblasts can be Improved by Considering Bone Marrow Blasts from Nonerythroid Cells
49. A TWO-STEP APPROACH FOR THE ANALYSIS OF SPLICING GENES IN MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS
50. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.